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ABSTRACT
Objective: To determine admissions diagnosis and outcomes of HIV-infected patients 
attending AMPATH ambulatory HIV-care clinics.
Design: Prospective cohort study.
Setting: Academic  Model for Prevention and Treatment of HIV/ AIDS (AMPATH) 
ambulatory HIV-care clinic in western Kenya.
Results: Between January 2005 and December 2006, 495 HIV-infected patients enrolled 
in AMPATH were admitted. Median age at admission was 38 years (range: 19 - 74), 62% 
females, 375 (76%) initiated cART a median 56 days (range: 1- 1288) before admission. 
Majority (53%) had pre-admission CD4 counts <100 cells/ml and 23% had counts 
>200 cells/ml. Common admissions diagnoses were: tuberculosis (27%); pneumonia 
(15%); meningitis (11%); diarrhoea (11%); malaria (6%); severe anaemia (4%); and 
toxoplasmosis (3%). Deaths occurred in 147 (30%) patients who enrolled at AMPATH 
a median 44 days (range: 1 - 711) before admission and died a median 41 days (range: 
1 -713) after initiating cART. Tuberculosis (27%) and meningitis (14%) were the most 
common diagnoses in the deceased. Median admission duration was six days (range: 
1 - 30) for deceased patients and eight days (range: I - 44) for survivors (P=0.0024). 
Deceased patients enrolled in AMPATH or initiated cART more recently, had lower 
CD4 counts and were more frequently lost to follow-up than survivors (P<0.05 for each 
comparison). Initiation of cART before admission and clinic appointment adherence 
were independent predictors of survival.
Conclusion: Although high mortality rate is seen in HIV-infected in-patients, those 
initiating cART before admission were more likely to survive.
INTRODUCTION
The number of HIV-infected patients on combination 
antiretroviral therapy (cART) in middle and low 
income countries has rapidly increased and is 
projected to exceed 3.3 million by the end of 2008 
(1, 2). In Kenya the National AIDS and STI Control 
Programme (NASCOP) initiated a free public 
antiretroviral treatment programme in 2005 and as 
of December 2007, 172,000 HIV-infected patients had 
initiated cART. However, close to 30,000 of these 
patients had either died or were lost to follow-up (3). 
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In the developed world, where genotypic resistance 
testing and 3rd line cART are standard of care, HIV 
disease computer simulations estimate the post-cART 
initiation life expectancy of a HIV-infected person to 
be between 24 and 36 years (4-6). Although cART is 
equally successful in African patients (7-12) morbidity 
and mortality remain high (13, 14). Some of the 
reasons explicating this include: incomplete access to 
HIV-care; later start of antiretrovirals (CD4 cell count 
<200/ml vs. 350/ml); absence of 2nd line regimes in 
some areas; and complete absence of genotyping 
and 3rd line regimes. For these and other reasons, 
sub-Saharan Africa lags behind in HIV treatment and 
care provision and bears the brunt of HIV associated 
morbidity and mortality. Out of the 2 million HIV/
AIDS related deaths worldwide in 2007, sub-Saharan 
Africa accounted for 1.6 million (15).
 This prospective cohort study was undertaken 
at a public referral hospital in western Kenya where a 
free antiretroviral treatment programme has been in 
place since November 2001 (16). HIV infected patients 
enrolled in an ambulatory HIV care programme who 
got admitted to the adult medical wards were studied 
in order to determine their admissions diagnosis, 
length of stay in the ward, status and duration on 
cART and outcomes of their admission. We also 
sought to establish characteristics that specifically put 
HIV-infected patients at risk of dying despite having 
been enrolled in an antiretroviral programme.
MATERIALS AND METHODS
Design: The Moi University School of Medicine/
Moi Teaching and Referral Hospital Institutional 
Research and Ethics Committee (IREC) and Indiana 
University Purdue University at Indianapolis/Clarion 
Institutional Review Board (lRB) approved this study. 
Patient demographic and clinical data were collected 
prospectively from adult HIV-infected patients 
admitted in the medical wards of the Moi Teaching 
and Referral Hospital (MTRH) between January 2005 
and December 2006. Additional demographic, clinical 
and laboratory data were extracted from the AMPATH 
Medical Records System (AMRS), a fully electronic 
database of HIV-infected patients (17, 18).
Study site: MTRH, a national referral hospital in 
western Kenya, serves a population of 13 million 
people [(40%) of Kenya’s population, national HIV 
prevalence of 6.7% (19, 20)]. MTRH also serves as 
the teaching hospital for Moi University School 
of Medicine (MUSoM). The total bed capacity at 
MTRH is 500 with 140 of these in two adult medical 
wards. Within this teaching hospital all inpatient 
management is overseen by physicians from the 
Department of Medicine of MUSoM. All ambulatory 
HIV-care in MTRH is provided by the Academic 
Model for Prevention and Treatment of HIV/AIDS 
(AMPATH) programme. The USAID-AMPATH 
Partnership (referred to as AMPATH hereafter) is 
a collaboration between MTRH, MUSoM and a 
consortium of universities from North America led by 
Indiana University School of Medicine and is funded 
in large part by USAID. The programme has been 
providing comprehensive ambulatory care to HIV-
infected patients in western Kenya since November 
2001. AMPATH provides an uninterrupted supply 
of antiretrovirals and medicines for treatment and 
prevention of opportunistic infections.
 In the time period of this study AMPATH 
clinicians’ involvement in care provision for admitted 
HIV-infected patients at MTRH included: clinical 
decision support with regard to antiretroviral 
initiation discontinuation and management of 
severe side effects; ensuring that antiretrovirals were 
uninterrupted during the admission; and supervision 
of a universal provider initiated HIV counselling and 
testing (PITC) programme for inpatients who had not 
been tested and/or enrolled in AMPATH.
Subjects: Analyses included all HIV-infected adult 
patients who got admitted to the adult medical wards 
at MTRH between January 2005 and December 2006 
and had previously been enrolled in the AMPATH 
ambulatory care programme.
Data collection and management: Using a standardised 
form, a research assistant recorded, on a daily basis, 
the details of AMPATH patients admitted in the 
adult medical wards. Information collected included 
AMPATH identification number, admission diagnosis, 
laboratory and radiological test results, treatment 
given, the length of stay on the ward and the final 
admission outcome (discharge or death). All data 
collected were entered into an admissions database 
programmed in MS Excel®. In order to complete the 
patients’ profiles, the AMPATH identification number 
was used to link admissions data with pre-admission 
electronic data stored in the AMPATH Medical 
Record System (AMRS), a fully secure electronic 
medical database (http://amrs.iukenya.org). These data 
included baseline data such as age, sex, employment 
status, marital status, weight, WHO stage and CD4 
cell count closest but prior to admission and clinic 
appointment and medications adherence. All patient 
data were de-identified prior to analysis.
Data analysis: Events duration such as patient 
enrollment at AMPATH to admission, duration on 
cART and duration from admission to discharge or 
death were calculated. We independently determined 
the accuracy and likelihood of each diagnosis made 
by analysing patient history, physical examination 
results, progress notes and laboratory and radiological 
results available from hospital files of patients included 
in this study. For patients with multiple admissions, 
any subsequent diagnoses were excluded from this 
analysis if they were judged to be either unresolved 
or a continuation of initial diagnosis. All antiretroviral 
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medications, adherence to antiretroviral and clinic 
appointment and lost to follow-up data were abstracted 
from the AMPATH database. Loss to follow-up was 
defined as missing ambulatory clinic appointment for 
three consecutive months if on cART or six months if the 
patient had not initiated cART. Descriptive statistical 
analyses such as median and range were generated for 
continuous variables. Frequency tables were produced 
for categorical variables and these were compared via 
the Chi-square and Wilcoxon tests. Variables found to 
be statistically significant at the 20% level were included 
in a multivariate logistic regression model to determine 
those that could be used independently to predict 
survival. Since we found that the majority of patients 
who died were not on cART treatment adherence data 
were not included in the final model since this data is 
collected for patients on cART only.
RESULTS
Between January 2005 and December 2006, 495 
patients enrolled in AMPATH for ambulatory care 
contributed 524 admissions to the general adult 
medical wards at MTRH. The median age at admission 
was 38 years (range: 19-74 years), 62% were female, 
55% were married, 90% had some formal education, 
64% were employed and 375/495 (76%) had initiated 
cART prior to admission. An additional 92 (19%) 
patients initiated cART during admission. In total, 
467/495 (94%) of this cohort of patients were on 
cART. A total of 952 diagnoses were made with 
majority (58%) of patients presenting with multiple 
complications. A diagnosis was not established in 
16 (2%) of the patients, 15 (94%) of who died. Of 
all the diagnosis made (Table 1) tuberculosis was 
the commonest (27%) complication followed by 
pneumonia (15%) meningitis (11%) diarrhoea (11%), 
malaria (6%), severe anaemia (4%) and toxoplasmosis 
(3%). Pulmonary tuberculosis accounted for 79% 
of all the cases of tuberculosis. Of the 137 patients 
with a sputum smear result, 87 (73%) were positive. 
Bronchopneumonia, pneumocystis pneumonia and 
lobar pneumonia accounted for 39%, 36% and 24% 
of all cases of pneumonia respectively. Excluding 
tuberculous meningitis, cryptococcal meningitis 
accounted for 65% of all cases of meningitis and 
97% of cases of chronic meningitis. Other relatively 
common admission diagnoses included Kaposi’s 
sarcoma, stroke, chronic liver disease and hepatitis. 
Details of the relatively frequency of these and other 
complications are provided in Table I.
Table 1
Admission diagnoses in 495 HIV-infected inpatients at the Moi Teaching and Referral 
Hospital in western Kenya
Diagnosis In 495 admitted In 147 patients
 patients (n= 952) that died (n= 232)
Tuberculosis 257 (27%) 63 (27%)
 Pulmonary tuberculosis 202 51
 Sputum smear positive 87 3
 Sputum smear negative 50 16
 No sputum smear results 65 32
 Tuberculous meningitis  27 7
 Tuberculous adenitis  12 1
 Tuberculous pleural effusion  5 -
 Milliary tuberculosis  4 1
 Tuberculosis of the spine 4 3
 Tuberculous peritonitis 2 -
 Tuberculous pericarditis 1 -
Pneumonia 140 (15%) 30 (13%)
 Bronchopneumonia  55 14
 Pneumocystis pneumonia 51 9
 Lobar pneumonia 34 7
Meningitis 104 (11%) 33 (14%)
 Cryptococcal meningitis 68 24
 Acute bacterial meningitis 34 9
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 Chronic (undetermined aetiology) 2 1
Diarrhoea 102 (11%) 22 (9%)
 Dysentery 3 -
Malaria 57 (6%) 9 (4%)
CNC disorders: Stroke, encephalitis,  39 (4%) 4
encephalopathy, acute psychoses, 
depression, dementia, paraparesis/plegia,
quadruparesis/plegia, peripheral neuropathy, 
brain abscess, ataxia
Severe anaemia 37 (4%) 4
Infective: Salmonella typhi, cellulites,  32 (3%) 2
otitis media PID, tetanus, HZ, 
CMV retinitis, measles, UTI, 
nephritis, cholecystitis, PUO 
Metabolic: DM, HTN, ARF, CRF,  32 (3%) 7
CHF, acute asthma, hypoglycaemia, 
shock, pancreatitis
Toxoplasmosis 26 (3%) 11 (5%)
Malignancies: Kaposi’s sarcoma, lymphoma  22 (2%) 9 (4%)
chronic liver disease, jaundice, hepatitis  20 (2%) 3
Candidiasis: oro-pharyngeal, oesophageal  18 (2%) 2
Peptic ulcer disease (PUD) 14 (1.5%) 1
Deep vein thrombosis (DVT) 10 (1%) 2
Haematological: bleeding, thrombocytopaenia, 9 (1%) 3
splenomegaly, pancytopenia
Adverse drug reaction: SJS*, hepatitis 7 (11%) 2
Nutritional: HIV wasting syndrome,pellagra 6 (1%) 1
Others; Addison’s disease, pulmonary embolism 3 (0.5%) -
Undetermined diagnosis 16 (2%) 15 (6%)
*More diagnoses than patients since some patients had multiple diagnosis or were admittered 
more than once.
PID = pelvic inflammatory disease; HZ = herpes zoster; CMV = cytomegalovirus: UTI = urinary 
tract infection; PUO = pyrexia of unknown origin; DM = diabetes mellitus; HTN = hypertension; 
ARF = acute renal failure; CRF = chronic renal failure; CCF = chronic heart failure; SJS = Stephen 
Johnson’s Syndrome
 Out of all the admissions, 348 (70%) patients 
survived and 147 (30%) died. The characteristics 
of patients who survived and those who died are 
shown in Table 2. Age, sex, marital and educational 
status were comparable between the two groups. 
There were no significant differences in WHO 
staging closest but prior to admission (p = 0.2766). 
However, patients who died were more likely to be 
more severely immunosuppressed than those who 
survived (p=0.0059), had been enrolled in AMPATH 
more recently, (median 44 vs. 70 days; p = 0.0248) and 
were on antiretrovirals for a shorter duration of time 
(median 41 vs. 67 days; p = 0.0022). Surviving patients 
were also more likely to have initiated antiretroviral 
treatment prior to admission (p<0.0006). The median 
duration of stay in the ward for surviving patients 
was eight days (range: 1 - 44 days) and six days 
(range: 1 - 30 days) for those who died (p = 0.0024). 
Patients who died were also more likely to have been 
previously lost to follow-up from the ambulatory care 
clinic at AMPATH (p<0.0001). For patients who died 
tuberculosis (27%), meningitis (14%), pneumonia 
(13%), diarrhoea (9%), severe anaemia (6%) and 
toxoplasmosis (5%) were the main complications 
diagnosed, which reflects a similar trend to the 
entire cohort of HIV-infected patients under study. 
In a multivariate logistic regression model that 
controlled for gender, cART status and duration, 
duration in AMPATH care, CD4 cell count and loss 
to follow-up, we found that patients were more likely 
to survive if they initiated cART prior to admission, 
(odds ratio 8; 95%, C1 2-142). We also established 
November 2008 EAST AFRICAN MEDICAL JOURNAL   527
that patients adherent to their clinic appointments 
prior to admission had markedly increased chances 
of surviving index admission compared to those lost 
to follow-up (odds ratio 6; 95% CI 2 - 14). Gender and 
CD4 cell count were not significantly associated with 
admission’s outcome for this specific cohort.
DISCUSSION
While it is of major concern that HlV-infected patients 
with access to comprehensive HIV care should record 
such high mortality rates, we would like to note 
that the majority of these deaths occurred soon after 
enrolment in AMPATH and initiation of cART, if at 
all. This mirrors our earlier findings that most deaths 
in patients initiating cART occurred within the first 
two months of treatment (21). This suggests that 
implementing a more aggressive clinic or home-based 
follow-up programme might reduce early mortality. 
It is also evident that the patients we studied were 
severely immunosuppressed, had multiple severe 
diseases at admission and hence at the greatest risk 
for developing life-threatening complications. Since 
it can be very challenging to diagnose some of the 
opportunistic infections implicated in resource poor 
settings, we recommend that clinicians have a high 
index of suspicion and a low threshold for diagnosing 
and aggressively treating these and other diseases in 
admitted HIV-infected patients.
 It is not surprising that tuberculosis was common 
in this cohort since Kenya is listed as one of the ten 
countries with the highest burden of tuberculosis in the 
world (22). Previous pre cART studies on HIV-infected 
patients in Kenya have also shown a high prevalence 
of tuberculosis (23). However, the prevalence of 
tuberculosis in our patients was markedly lower 
(27%) than that reported (50%) in the study above. We 
speculate that this might be related to the fact that the 
majority of our patients were on cART. The finding 
of pulmonary tuberculosis as the commonest form of 
tuberculosis in these patients is consistent with that 
reported elsewhere (24). Since reactivation of latent 
tuberculous is common in HIV-infected patients (25), 
establishing tuberculosis screening and prevention 
programmes in the community might be an effective 
strategy to reduce the reservoir of Mycobacterium 
tuberculosis. Early recognition and diagnosis of HIV 
infection among community dwellers with subsequent 
administration of isoniazid preventive therapy (lPT) 
is another strategy that, if executed judiciously, has 
shown benefits in reducing tuberculosis reactivation 
in HlV-infected patients (25, 26).
 It is likely that some of our subjects on cART had 
immune reconstitution and inflammatory syndrome 
(IRIS) which is being increasingly recognised as 
an early complication associated with successful 
immune recovery. IRIS, which represents a reaction 
to a previously immunologically unrecognised or 
indolent infection, may occur in up to 30% of patients 
initiating cART and is of particular concern in high 
tuberculosis prevalence areas (27,28). IRIS has also 
been reported to occur in patients with cryptococcal 
meningitis. Pneumocystis pneumonia, Kaposi’s 
sarcoma, herpes zoster and herpes simplex infections 
(27-29), most of which were common diseases in this 
study. Diagnosis of IRIS is particularly challenging in 
this setup because its presentation is very similar to 
traditional opportunistic infections and resources for 
laboratory, radiological and pathological diagnosis are 
not often at hand to be of assistance (30). However, 
the knowledge generated from such research studies 
as this one can guide clinicians in making empiric 
clinical diagnosis for some of these conditions.
Study limitations: Some of the diagnoses made were 
based on clinical and radiological investigations 
without bacteriologic, immunologic or postmortem 
proof. Since the correctness of clinical diagnosis is 
heavily dependent on clinicians’ experience and 
judgment, and even though the investigators made 
efforts to verify each diagnosis, the accuracy of 
some of these diagnoses may vary. Other co-morbid 
conditions such as derangements in liver enzymes 
and electrolytes and their relative contribution 
to morbidity and mortality were not established. 
Similarly, the actual causes of death could not be 
determined since there were no postmortem data. 
Previous opportunistic infections, past admissions 
and their probable effect on current admission 
were not evaluated in this study. Due to financial 
constraints, plasma viral load tests are only performed 
on patients clinically failing cART, and hence were 
not included in this analysis.
In conclusion, the high death rates reported in this 
study occurred in a highly select cohort of HIV-
infected inpatients, a few of them having recently 
initiated cART at an ambulatory HIV care programme 
in western Kenya. Most of these inpatients were 
severely immunosuppressed hence at the greatest 
risk acquiring life threatening complications such 
as tuberculosis, meningitis and pneumonia. On the 
contrary, patients that had been enrolled and initiated 
cART for longer duration were likely to survive. We 
would, therefore like to emphasise the need for early 
and accurate diagnosis of HIV, aggressive treatment of 
opportunistic infections in order to reduce morbidity 
and immortality and implementation of programmes 
for close follow-up early in the course of cART with 
interventions to increase adherence to treatment and 
clinic appointments. Future research should study the 
effects of such interventions on early morbidity and 
mortality in cART-treated HIV-infected adults.
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